Sign In
Buy PFE
$26.04
+0.345 (+1.34%)
At Close: Jun 05, 2026
Is This a New Reason to Buy Pfizer Stock Hand Over Fist?
08:45am, Friday, 29'th Nov 2024
Despite Pfizer's (PFE 0.23%) recent struggles with falling earnings and a bid by an activist investor to unseat its leadership, the pharma juggernaut is still actively advancing its core priorities an
Are Investors Undervaluing Pfizer (PFE) Right Now?
10:41am, Thursday, 28'th Nov 2024
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest
Eli Lilly, Pfizer, and AstraZeneca: 2025 Vaccine Makers to Watch
08:01am, Thursday, 28'th Nov 2024
Leading vaccine makers like Eli Lilly and Co. NYSE: LLY, Pfizer Inc. NYSE: PFE, and AstraZeneca plc NASDAQ: AZN may have faded from the spotlight since the peak of the COVID-19 pandemic, but now there
5 Blue Chips Yielding Over 7% I'm Considering Buying, And So Should You
07:00am, Thursday, 28'th Nov 2024
I'm seeking 6%-plus yielding blue-chip bargains for my family's portfolio, with a focus on long-term income growth and minimal volatility. My ZEUS Family portfolio strategy involves annual rebalancing
Is Pfizer Stock in Trouble?
06:17am, Thursday, 28'th Nov 2024
One stock that just can't seem to catch a break of late is Pfizer (PFE 0.23%). Even though it posted some decent earnings numbers, investors can't shake the fear that the business is facing daunting h
High-Quality Dividend Growth Stocks Near 52-Week Lows: Pfizer Is Fun
06:16am, Wednesday, 27'th Nov 2024
A list of high-quality dividend-growth stocks trading near 52-week lows is evaluated based on historical and future fair values. Pfizer's financial health is concerning, with unsustainable dividend pa
Billionaires Are Buying Up Beaten-Down Pfizer Stock. Should You Follow Their Lead?
05:31am, Wednesday, 27'th Nov 2024
Nobody can predict the future, but it's not hard to imagine increasing pharmaceutical sales. In 2022, prescription drug spending in the U.S. climbed more than 8% to reach $406 billion.
Pfizer Inc. (PFE) is Attracting Investor Attention: Here is What You Should Know
10:05am, Tuesday, 26'th Nov 2024
Pfizer (PFE) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Current, Future and Former Dividend Aristocrats Yielding Over 4% to Buy in November 2024
08:47am, Tuesday, 26'th Nov 2024
Maintaining dividend aristocrat status isn't easy, as it requires companies to pay out dividends consistently (and raise them each year) for 25 consecutive years, while maintaining a $3 billion market
Should You Buy the 3 Highest-Paying Dividend Stocks in the S&P 500?
08:30am, Tuesday, 26'th Nov 2024
The power of owning dividend-paying stocks is often underappreciated. Consider, for example, that a study by Hartford Funds and Ned Davis Research found that between 1973 and 2023, companies that grew
2 High-Yield Dividend Stocks to Buy Now for a Lifetime of Passive Income
05:03am, Tuesday, 26'th Nov 2024
Investors looking for a way to pump up their passive income streams want to turn their attention toward the pharmaceutical industry. From the end of 2022 through Nov. 22, the benchmark S&P 500 index r
Mizuho's Jared Holz on what Trump's FDA pick means for biotech innovation
06:44pm, Monday, 25'th Nov 2024
Mizuho's Jared Holz joins 'Fast Money' to talk what's next for biopharma space after president-elect Trump names his pick for FDA head.
One Sector Has Underperformed Massively: These 4 Blue-Chip Dividend Giants Are Huge 2025 Plays
11:46am, Monday, 25'th Nov 2024
Key Points Donald Trump's victory is positive for the stock market.
FDA Approves BridgeBio Pharma's Drug For Rare Heart Disease, Poised To Challenge Pfizer In Lucrative Yet Competitive Market
09:03am, Monday, 25'th Nov 2024
On Friday, the FDA approved BridgeBio Pharma, Inc.'s BBIO Attruby (acoramidis), an orally-administered near-complete (≥90%) stabilizer of Transthyretin (TTR) for adults with ATTR-CM to reduce cardio
Nvidia's Profit Ruled Last Quarter — Now It's These 8 Stocks' Turn
08:00am, Monday, 25'th Nov 2024
Nvidia reported third-quarter profit that doubled — putting it near the top of the S&P 500's growth. But look for profit growth elsewhere.
